Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026

Bausch Health (BHC) will release its third quarter 2026 financial results after market close on October 28, 2026.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Bausch Health (BHC) will release its third quarter 2026 financial results after market close on October 28, 2026.

A live conference call and webcast will follow at 5:00 p.m. U.S. EDT to discuss results and provide a business update. Materials will be available on the company's Investor Relations website before the call, with a replay available afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/06/2026 - 07:00 AM

LAVAL, QC, Oct. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Conference Call Details

Date: Wednesday, October 28, 2026

Time: 5:00 p.m. U.S. EDT

Webcast: http://ir.bauschhealth.com/events-and-presentations

A replay of the conference call will be available on the Investor Relations website.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.

Investor Contact:	Media Contact:
Garen Sarafian	Alexis Navratil
ir@bauschhealth.com	corporate.communications@bauschhealth.com
(877) 281-6642 (toll-free)	(848) 264-0934

BHC-FINANCIAL